SAGE – Sage Therapeutics, Inc.

Sage Therapeutics, Inc.

SAGE

$6.55

Name : Sage Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $409,852,480.00

EPSttm : -5.8

Sage Therapeutics, Inc.

$6.55

0.98%

$0.065

Float Short %

8.48

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

0.17

EPS Last/This Y

3.02

EPS This/Next Y

0.36

Price

6.61

Target Price

8.18

Analyst Recom

2.83

Performance Q

-8.07

Relative Volume

0.7

Beta

0.21

Ticker: SAGE

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	SAGE	7.4	0.34	1.14	14251
2025-04-15	SAGE	7.54	0.34	0.00	14286
2025-04-16	SAGE	7.36	0.34	0.35	14365
2025-04-17	SAGE	7.42	0.34	0.00	14421
2025-04-18	SAGE	7.43	0.34	0.00	14421
2025-04-21	SAGE	7.45	0.38	0.00	12962
2025-04-22	SAGE	7.68	0.38	0.00	13147
2025-04-23	SAGE	7.61	0.38	0.00	13143
2025-04-24	SAGE	7.78	0.37	53.00	13240
2025-04-25	SAGE	7.79	0.37744844025288	0	13291
2025-04-28	SAGE	7.77	0.37342356198093	0	13395
2025-04-29	SAGE	7.59	0.37	0.00	13507
2025-04-30	SAGE	7.28	0.37	2.28	13610
2025-05-01	SAGE	7.47	0.41	0.00	14269
2025-05-02	SAGE	7.29	0.40	2.00	14548
2025-05-05	SAGE	7.17	0.40	0.09	14549
2025-05-06	SAGE	6.85	0.40	0.21	14698
2025-05-07	SAGE	6.81	0.41	0.01	14754
2025-05-08	SAGE	6.7	0.39	0.06	15091
2025-05-09	SAGE	6.57	0.39	0.06	15239
2025-05-12	SAGE	6.76	0.25	0.00	13802
2025-05-13	SAGE	6.61	0.25	2.33	13785
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	SAGE	7.40	45.2	-	-3.70
2025-04-15	SAGE	7.54	45.2	-	-3.70
2025-04-16	SAGE	7.38	45.2	-	-3.70
2025-04-17	SAGE	7.43	45.2	-	-3.70
2025-04-18	SAGE	7.43	45.2	-	-3.49
2025-04-21	SAGE	7.45	45.6	-	-3.49
2025-04-22	SAGE	7.68	45.6	-	-3.49
2025-04-23	SAGE	7.62	45.6	-	-3.49
2025-04-24	SAGE	7.78	45.6	-	-3.49
2025-04-25	SAGE	7.79	45.6	-	-3.49
2025-04-28	SAGE	7.77	45.6	-	-3.49
2025-04-29	SAGE	7.60	45.6	-	-3.61
2025-04-30	SAGE	7.29	45.6	-	-3.61
2025-05-01	SAGE	7.48	45.6	-	-3.61
2025-05-02	SAGE	7.30	45.6	-	-3.70
2025-05-05	SAGE	7.17	45.6	-	-3.44
2025-05-06	SAGE	6.86	45.6	-	-3.44
2025-05-07	SAGE	6.82	45.6	-	-3.44
2025-05-08	SAGE	6.71	45.6	-	-3.44
2025-05-09	SAGE	6.57	45.6	-	-3.57
2025-05-12	SAGE	6.75	45.6	-	-3.57
2025-05-13	SAGE	6.61	44.7	-	-3.57
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	SAGE	0.00	-16.55	7.70
2025-04-15	SAGE	0.00	-16.55	7.70
2025-04-16	SAGE	0.00	-16.55	7.70
2025-04-17	SAGE	0.00	-16.55	7.70
2025-04-18	SAGE	0.00	-16.55	7.70
2025-04-21	SAGE	0.00	-16.74	7.70
2025-04-22	SAGE	0.00	-16.74	7.70
2025-04-23	SAGE	0.00	-16.74	7.70
2025-04-24	SAGE	0.00	-16.74	7.70
2025-04-25	SAGE	0.00	-16.74	7.70
2025-04-28	SAGE	0.00	-16.31	8.07
2025-04-29	SAGE	0.00	-16.31	8.07
2025-04-30	SAGE	0.00	-16.31	8.07
2025-05-01	SAGE	0.00	-16.31	7.92
2025-05-02	SAGE	0.00	-16.31	7.92
2025-05-05	SAGE	0.00	-16.03	7.92
2025-05-06	SAGE	0.00	-16.03	7.92
2025-05-07	SAGE	0.00	-16.03	7.92
2025-05-08	SAGE	0.00	-16.03	7.92
2025-05-09	SAGE	0.00	-16.03	7.92
2025-05-12	SAGE	0.00	-15.86	8.48
2025-05-13	SAGE	0.00	-15.86	8.48
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-1.01

Avg. EPS Est. Current Quarter

-0.94

Avg. EPS Est. Next Quarter

-0.84

Insider Transactions

Institutional Transactions

-15.86

Beta

0.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.3

Max Drawdown 5-Year %

-95.1

Target Price

8.18

P/E

Forward P/E

PEG

P/S

8.73

P/B

1.01

P/Free Cash Flow

EPS

-5.8

Average EPS Est. Cur. Y

-3.57

EPS Next Y. (Est.)

-3.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-747.61

Relative Volume

0.7

Return on Equity vs Sector %

-110.2

Return on Equity vs Industry %

-93.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

Sage Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 353

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

stock quote shares SAGE – Sage Therapeutics, Inc. Stock Price stock today

news today SAGE – Sage Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SAGE – Sage Therapeutics, Inc. yahoo finance google finance

stock history SAGE – Sage Therapeutics, Inc. invest stock market

stock prices SAGE premarket after hours

ticker SAGE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

SAGE – Sage Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SAGE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y